Alternative antiretroviral monitoring strategies for HIV-infected patients in east Africa: Opportunities to save more lives?

Journal of the International AIDS Society

Volumn 14, Issue 1, 2011, Pages

  Braithwaite, R Scott ^a   Nucifora, Kimberly A ^a   Yiannoutsos, Constantin T ^b   Musick, Beverly ^b   Kimaiyo, Sylvester ^c   Diero, Lameck ^c   Bacon, Melanie C ^d   Wools Kaloustian, Kara ^b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY   (United States)

^c MOI UNIVERSITY   (Kenya)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AFRICA; ARTICLE; CD4 LYMPHOCYTE COUNT; COMPUTER SIMULATION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; HEALTH INSURANCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNOLOGICAL PROCEDURES; MALE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; COST BENEFIT ANALYSIS; DRUG MONITORING; ECONOMICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; METHODOLOGY; PATHOLOGY; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

AFRICA, EASTERN; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DRUG MONITORING; HIV INFECTIONS; HUMANS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 79960869009     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.1186/1758-2652-14-38     Document Type: Article

References (29)

1. HIV viral load monitoring in resource-limited regions: optional or necessary? Calmy A, Ford N, Hirschel B, Reynolds SJ, Lynen L, Goemaere E, Garcia de la Vega F, Perrin L, Rodriguez W, Clin Infect Dis 2007 44 128 134 10.1086/510073 17143828 (Pubitemid 44968997)
2. Rational use of antiretroviral therapy in low-income and middle-income countries: optimizing regimen sequencing and switching. Elliott JH, Lynen L, Calmy A, De Luca A, Shafer RW, Zolfo M, Clotet B, Huffam S, Boucher CA, Cooper DA, Schapiro JM, AIDS 2008 22 2053 2067 10.1097/QAD.0b013e328309520d 18753937
3. Monitoring HIV treatment in resource-limited settings: reassuring news on the usefulness of CD4(+) cell counts. Fowler MG, Owor M, J Infect Dis 2009 199 1255 1257 10.1086/597618 19317627
4. Dried blood spots perform well in viral load monitoring of patients who receive antiretroviral treatment in rural Tanzania. Johannessen A, Garrido C, Zahonero N, Sandvik L, Naman E, Kivuyo SL, Kasubi MJ, Gundersen SG, Bruun JN, de Mendoza C, Clin Infect Dis 2009 49 976 981 10.1086/605502 19663598
5. Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model. Phillips AN, Pillay D, Miners AH, Bennett DE, Gilks CF, Lundgren JD, Lancet 2008 371 1443 1451 10.1016/S0140-6736(08)60624-8 18440426 (Pubitemid 351635534)
6. Viral load testing in resource-limited settings. Schooley RT, Clin Infect Dis 2007 44 139 140 10.1086/510090 17143830 (Pubitemid 44968999)
7. Antiretroviral therapy for HIV infection in adults and adolescents: Recommendations for a public health approach: 2010 revision. WHO, http://www.who.int/hiv/pub/arv/adult2010/en/index.html
8. Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring. ART-LINC of IeDEA Study Group, Keiser O, Tweya H, Boulle A, Braitstein P, Schecter M, Brinkhof MW, Dabis F, Tuboi S, Sprinz E, Pujades-Rodriguez M, Calmy A, Kumarasamy N, Nash D, Jahn A, MacPhail P, Luthy R, Wood R, Egger M, AIDS 2009 23 1867 1874 19531928
9. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. DART Trial Team, Mugyenyi P, Walker AS, Hakim J, Munderi P, Gibb DM, Kityo C, Reid A, Grosskurth H, Darbyshire JH, Ssali F, Bray D, Katabira E, Babiker AG, Gilks CF, Grosskurth H, Munderi P, Kabuye G, Nsibambi D, Kasirye R, Zalwango E, Nakazibwe M, Kikaire B, Nassuna G, Massa R, et al. Lancet 2010 375 123 131 20004464
10. Cost-effectiveness of HIV treatment in resource-poor settings - the case of Cote d'Ivoire. Goldie SJ, Yazdanpanah Y, Losina E, Weinstein MC, Anglaret X, Walensky RP, Hsu HE, Kimmel A, Holmes C, Kaplan JE, Freedberg KA, N Engl J Med 2006 355 1141 1153 10.1056/NEJMsa060247 16971720 (Pubitemid 44394920)
11. The cost effectiveness of antiretroviral treatment strategies in resource-limited settings. Bishai D, Colchero A, Durack DT, AIDS 2007 21 1333 1340 10.1097/QAD.0b013e328137709e 17545710 (Pubitemid 46883488)
12. Estimating the proportion of patients infected with HIV who will die of comorbid diseases. Braithwaite RS, Justice AC, Chang CC, Fusco JS, Raffanti SR, Wong JB, Roberts MS, Am J Med 2005 118 890 898 10.1016/j.amjmed.2004.12.034 16084183 (Pubitemid 41097468)
13. Influence of alternative thresholds for initiating HIV treatment on quality-adjusted life expectancy: a decision model. Braithwaite RS, Roberts MS, Chang CC, Goetz MB, Gibert CL, Rodriguez-Barradas MC, Shechter S, Schaefer A, Nucifora K, Koppenhaver R, Justice AC, Ann Intern Med 2008 148 178 185 18252681 (Pubitemid 351665505)
14. Estimating the rate of accumulating drug resistance mutations in the HIV genome. Braithwaite RS, Shechter S, Chang CC, Schaefer A, Roberts MS, Value Health 2007 10 204 213 10.1111/j.1524-4733.2007.00170.x 17532813 (Pubitemid 46802278)
15. Explaining variability in the relationship between antiretroviral adherence and HIV mutation accumulation. Braithwaite RS, Shechter S, Roberts MS, Schaefer A, Bangsberg DR, Harrigan PR, Justice AC, J Antimicrob Chemother 2006 58 1036 1043 10.1093/jac/dkl386 17023498
16. Understanding reasons for and outcomes of patients lost to follow-up in antiretroviral therapy programs in Africa through a sampling-based approach. Geng EH, Bangsberg DR, Musinguzi N, Emenyonu N, Bwana MB, Yiannoutsos CT, Glidden DV, Deeks SG, Martin JN, J Acquir Immune Defic Syndr 2010 53 405 411 10.1097/QAI.0b013e3181b843f0 19745753
17. Portfolio Selection. Markowitz H, J Finance 1952 53 405 411
18. Gold MR, Seigel JE, Russell LB, Weinstein MC, Cost-Effectiveness in Health and Medicine New York: Oxford University Press 1996
19. Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa. Mee P, Fielding KL, Charalambous S, Churchyard GJ, Grant AD, AIDS 2008 22 1971 1977 10.1097/QAD.0b013e32830e4cd8 18784460
20. WHO case definitions of HIV for surveillance and revised clinical staging and immunologic classification of HIV-related disease in adults and children. World Health Organization, http://www.who.int/hiv/pub/guidelines/hivstaging/en/ index.html
21. Update of the drug resistance mutations in HIV-1: December 2009. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, Schapiro JM, Richman DD, Top HIV Med 2009 17 138 145 20068260
22. Adherence, virological and immunological outcomes for HIV-infected veterans starting combination antiretroviral therapies. Braithwaite RS, Kozal MJ, Chang CC, Roberts MS, Fultz SL, Goetz MB, Gibert C, Rodriguez-Barradas M, Mole L, Justice AC, AIDS 2007 21 1579 1589 10.1097/QAD.0b013e3281532b31 17630553 (Pubitemid 47075479)
23. Quantifying the decrement in utility from perceived side effects of combination antiretroviral therapies in patients with HIV. Braithwaite RS, Goulet J, Kudel I, Tsevat J, Justice AC, Value Health 2008 11 975 979 10.1111/j.1524-4733.2007.00315.x 18225989
24. The cost-effectiveness of preventing AIDS-related opportunistic infections. Freedberg KA, Scharfstein JA, Seage GR, Losina E, Weinstein MC, Craven DE, Paltiel AD, JAMA 1998 279 130 136 10.1001/jama.279.2.130 9440663 (Pubitemid 28068303)
25. Red Book. Pharmacy's Fundamental Reference PDR Network 113 2009 20696721
26. World Health Statistics. http://www.who.int/whosis/whostat/EN-WHS08-Full. pdf
27. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. Mills EJ, Nachega JB, Buchan I, Orbinski J, Attaran A, Singh S, et al. JAMA 2006 296 679 690 10.1001/jama.296.6.679 16896111 (Pubitemid 44200639)
28. Sampling-based approaches to improve estimation of mortality among patient dropouts: experience from a large PEPFAR-funded program in Western Kenya. Yiannoutsos CT, An MW, Frangakis CE, Musick BS, Braitstein P, Wools-Kaloustian K, et al. PLoS One 2008 3 3843 10.1371/journal.pone.0003843 19048109
29. Veterans Aging Cohort Study (VACS): Overview and description. Justice AC, Dombrowski E, Conigliaro J, Fultz SL, Gibson D, Madenwald T, et al. Med Care 2006 44 13 24 10.1097/01.mlr.0000223741.02074.66 16849964 (Pubitemid 44284253)